Aim: Serum low-density lipoprotein cholesterol (LDL-C) increases during treatment of chronic hepatitis C (CHC) with interferon-free direct-acting antivirals (DAAs). We sought to compare the changes of serum lipid profiles caused by three regimens.
INTRODUCTION
H EPATITIS C VIRUS (HCV) affects 130-210 million people worldwide and HCV infection is a major risk factor for cirrhosis and hepatocellular carcinoma. 1 Until just a few years ago, the recommended treatment for chronic hepatitis C (CHC) was combination therapy consisting of pegylated-interferon (IFN)-α plus ribavirin (RBV). 2 Over the last several years, the management of CHC has improved dramatically with the introduction of direct-acting antivirals (DAAs) and the time to HCV eradication has been reduced. 3, 4 In 2014, for patients infected with HCV genotype 1b (HCV-GT1b), daclatasvir (DCV) (Bristol-Myers Squibb, Tokyo, Japan), a pan-genotypic non-structural protein 5A (NS5A) inhibitor, plus asunaprevir (ASV) (Bristol-Myers Squibb), an NS3 protease inhibitor, combination therapy (DCV/ASV) was approved in Japan as the first IFN-free regimen. 5 Subsequently, sofosbuvir (SOF), a nucleotide analog HCV NS5B polymerase inhibitor, plus ledipasvir (LDV), an NS5A inhibitor, combination therapy (Gilead Sciences, Tokyo, Japan) has been available in Japan since 2015 for patients infected with HCV-GT1b. 6 For patients infected with HCV genotype 2 (HCV-GT2), SOF (Gilead Sciences), which should be used with RBV (MSD, Tokyo, Japan or Chugai Pharmaceutical, Tokyo, Japan), a synthetic nucleoside analog of ribofuranose, has been available in combination since 2015. 7 Now, HCV can be eradicated by 12 weeks of DAA treatment with high probability and without obvious side-effects. 8 The rates of sustained virologic response (SVR) to DAA treatment has been reported to be >95% in patients infected with HCV-GT1 6 or HCV-GT2. 7 Hepatitis C virus infection is considered to alter the host lipid metabolism, the virus uses host lipids in every step of its replication cycle. 9, 10 Highly infectious HCV particles coated with lipids are secreted from the liver; apolipoprotein C and E are present on the surface. 11 This finding indicates that there is a close association between infectious HCV particles and lipoprotein metabolism. 12 Consequently, HCV is thought to affect the host lipid metabolism through its replication process.
Studies of serum lipid profiles in patients with CHC who achieved SVR have been reported. Serum total cholesterol (TC) levels in patients who were treated with IFN-based therapy and achieved SVR increased after therapy. 13, 14 However, changes of lipid metabolism during and after IFN-based therapy are not easily evaluated because of the long treatment period and severe sideeffects, which can be detrimental to the host nutritional state and may affect the serum lipid profiles. In contrast, IFN-free DAA treatment has few side-effects that can influence the nutritional state. In addition, the duration of DAA treatment is shorter than that of IFN-based therapy. Therefore, the changes of serum lipid profile during and after DAA treatment should be better defined.
In the post-IFN era, a few recent studies of IFN-free DAA treatment have been reported. Patients infected persistently with HCV-GT1 and treated with SOF/RBV showed an increase in serum low-density lipoprotein cholesterol (LDL-C) and a decrease in serum triglyceride (TG). 15 Another report suggested that the serum TC level increases soon after initiation of SOF/LDV and falls below the baseline level after treatment failure. 16 However, the effect of DAA therapy on lipid metabolism is still not clear.
In this study, longitudinal changes in serum lipid profiles during and after DAA treatment were examined in patients infected with HCV-GT1b and treated with DCV/ASV or SOF/LDV, and in patients infected with HCV-GT2 and treated with SOF/RBV. Here, the differences in serum lipid profiles among the three DAA treatment protocols are elucidated over a sufficient period.
METHODS

Ethical standards
W RITTEN INFORMED CONSENT was obtained from each patient and the study protocol was approved by the Institutional Review Board of Nagoya City University (Nagoya, Japan) in accordance with the Declaration of Helsinki (acceptance nos. 1002-2 and 00000866-2).
Patients
A total of 216 patients chronically infected with HCV were enrolled. All patients started one of the IFN-free DAA treatment regimens at Nagoya City University Hospital between September 2014 and April 2016. Of the 216 patients, 170 were infected with HCV-GT1b and 46 were infected with HCV-GT2. Of the patients infected with HCV-GT1b, 85 were treated with DCV/ASV, and 85 were treated with SOF/LDV. The 46 patients infected with HCV-GT2 were treated with SOF/RBV.
Therapeutic protocols
The protocol for DCV/ASV was oral administration of DCV (60 mg) once daily and ASV (100 mg) twice daily for 24 weeks. The protocol for SOF/LDV was oral administration of one tablet of combination drug containing 400 mg SOF and 90 mg LDV, once daily for 12 weeks. That for SOF/RBV was oral administration of SOF (400 mg) once daily and RBV (600 mg, 800 mg, or 1000 mg, depending on body weight) twice daily for 12 weeks.
Study design
Fasting blood samples were collected and serum lipid profiles were examined. For the patients treated with SOF/LDV or SOF/RBV, serum lipid profiles were measured at baseline, 4 weeks (4w), 8w, and 12w during therapy. For the patients treated with DCV/ASV, serum lipid profiles were measured at baseline, 4w, 8w, 12w, and 24w during therapy. Subsequently, the serum lipid levels of each group were measured at 12 and 24 weeks after the end of treatment (post 12 weeks [p12w] and p24w); p24w was the end-point of this study. Longitudinal changes in serum lipid profiles through the observation period were examined.
To compare changes in serum lipids between the patients treated with DCV/ASV, SOF/LDV, and SOF/RBV, the value of baseline serum TC, LDL-C, high-density lipoprotein cholesterol (HDL-C) and TG was subtracted from the value of TC, LDL-C, HDL-C, or TG at 4w, 8w, 12w, 24w (only the patients treated with DCV/ASV), p12w, and p24w. Then, the differences of the subtracted data, denoted as ΔTC, ΔLDL-C, ΔHDL-C, and ΔTG, were compared for the patients treated with DCV/ASV, SOF/LDV, and SOF/RBV.
Demographic data and laboratory tests
The demographic data, gender, and age at initiation of therapy were collated. Aspartate 2-oxoglutarate aminotransferase (AST), alanine 2-oxoglutarate aminotransferase (ALT), platelet count (PLT), serum albumin, cholinesterase, TC, LDL-C, HDL-C, TG, and Fibrosis-4 index (FIB-4 index) were included in the basic laboratory data. The FIB-4 index was calculated according to the following equation:
}. The serum levels of TC, LDL-C, HDL-C, and TG were measured using commercial kits (Sysmex, Kobe, Japan).
Routine measurements of HCV RNA were carried out using the Cobas AmpliPrep/Cobas TaqMan HCV Test, version 2.0 (Roche Diagnostics, Tokyo, Japan). Hepatitis C virus RNA was examined every 4 weeks until the end-point of the study. SVR24 was defined as undetectable HCV RNA in a serum specimen taken 24 weeks after the end of treatment. 17 
Statistical analysis
All statistical analyses were carried out using Ekuseru-Toukei 2012 software, version 1.02 (Social Survey Research Information, Tokyo, Japan). Statistical validity of the analyzed data calculated by this software is thought to be equivalent to SPSS software (personal communication from the provider). Continuous data are expressed as means ± standard deviations. Tukey-Kramer's method was used to compare data between the patients treated with DCV/ASV, SOF/LDV, and SOF/RBV. Longitudinal changes in the same group were compared using the paired Student's t-test.
A two-tailed probability (P) value of <0.05 was considered to be significant.
RESULTS
Patient characteristics
Sixty-nine (81.2%) of 85 patients treated with DCV/ASV, 84 (98.8%) of 85 patients treated with SOF/LDV, and 45 (97.8%) of 46 patients treated with SOF/RBV achieved SVR24. Data from the patients who achieved SVR24 were analyzed.
Patient characteristics are shown in Table 1 . The mean age of the patients treated with DCV/ASV was significantly higher than those with SOF/LDV and SOF/RBV (P = 0.027 and 0.003, respectively). The differences in PLT and the FIB-4 index between patients treated with DCV/ASV and SOF/LDV were significant (P = 0.041 and 0.034, respectively). In the serum lipid profiles at baseline, the difference in TG levels between the patients treated with DCV/ASV and SOF/LDV was significant (P = 0.033).
Changes in serum lipid levels in patients treated with DCV/ASV
Longitudinal changes in serum TC, LDL-C, HDL-C, and TG levels in patients treated with DCV/ASV are shown in Figure 1 .
Serum TC levels increased throughout the observation period and the increases between baseline and 24w, between baseline and p12w, and between baseline and p24w were significant (P = 0.019, 0.001, and <0.0001, respectively) (Fig. 1a) . Serum LDL-C levels also increased throughout the observation period. The longitudinal changes of the serum LDL-C levels were similar to those of the serum TC levels. The increases between baseline and p12w and between baseline and p24w were significant (P = 0.011, and <0.001, respectively) (Fig. 1b) . These significant differences were observed among individual patients. Serum HDL-C levels also increased throughout the treatment period. Serum
However, no significant increases were observed (Fig. 1c) . There was no significant change in serum TG levels throughout the observation period (Fig. 1d) .
Changes in serum lipid levels in patients treated with SOF/LDV Longitudinal changes in serum TC, LDL-C, HDL-C, and TG levels in the patients treated with SOF/LDV are shown in Figure 2 .
Serum TC levels increased early during the treatment period and the increases between baseline and 4w, between baseline and 8w, and between baseline and 12w were significant (all P < 0.0001). The serum TC level peaked at 8w and decreased gradually from 8w to p12w; the decreases between 8w and p12w and between 8w and p24w were significant (P = 0.039, and 0.044, respectively) (Fig. 2a) . The longitudinal changes of serum LDL-C levels were similar to those of the serum TC levels. Serum LDL-C levels also increased early during 
the treatment period. The increases between baseline and 4w, between baseline and 8w, and between baseline and 12w were significant (P = 0.004, 0.003, and 0.003, respectively). These significant differences were observed among individual patients. The serum LDL-C level peaked at 8w and decreased gradually from 8w to p12w. However, no significant decreases were observed (Fig. 2b) . Serum HDL-C levels also increased early during the treatment period. The level peaked at 8w and decreased gradually from 8w to p12w. However, no significant differences were observed (Fig. 2c) . There was no significant change in serum TG levels throughout the observation period (Fig. 2d) .
Changes in serum lipid levels in patients treated with SOF/RBV
Longitudinal changes in serum TC, LDL-C, HDL-C, and TG levels in patients treated with SOF/RBV are shown in Figure 3 . No significant changes in serum TC levels (Fig. 3a) , LDL-C levels (Fig. 3b) , HDL-C levels (Fig. 3c) , or TG levels Figure 2 Longitudinal changes in serum total cholesterol (TC) (a), low-density lipoprotein cholesterol (LDL-C) (b), high-density lipoprotein cholesterol (HDL-C) (c), and triglyceride (TG) (d) in patients with chronic hepatitis C infection treated with sofosbuvir and ledipasvir. Mean values of serum TC, LDL-C, HDL-C, and TG at baseline, 4 weeks (4w), 8w, and 12w during the treatment period and 12 and 24 weeks after the treatment period (p12w and p24w, respectively) are plotted. Vertical lines indicate the range of means ± standard deviations. Statistical significance of the difference from baseline is indicated in the upper part of each graph. At p12w and p24w, statistical significance between 12w and p12w and p24w is indicated in the lower part of each graph.
( Fig. 3d) were observed throughout the observation period.
Comparison of changes in serum lipid levels between patients treated with DCV/ASV, SOF/LDV, and SOF/RBV
The ΔTC values of patients treated with SOF/LDV were consistently higher than those of patients treated with DCV/ASV, during the treatment period. The ΔTC values of patients treated with DCV/ASV were consistently higher than those of patients treated with SOF/LDV, during the post-treatment period. In contrast, the ΔTC values of patients treated with SOF/RBV remained almost stable during the treatment period and increased during the post-treatment period. During the treatment period, the increases in the ΔTC values of patients treated with DCV/ASV or SOF/RBV were smaller than those of patients treated with SOF/LDV at each time point. During the posttreatment period, the increases of patients treated with SOF/LDV or SOF/RBV were larger than those of patients treated with DCV/ASV (Fig. 4a) .
The changes of the ΔLDL-C values of patients treated with DCV/ASV, SOF/LDV, or SOF/RBV were similar to those of the ΔTC values for each treatment regimen. smaller than those of the patients treated with SOF/LDV, at each time point. During the post-treatment period, the increases in patients treated with SOF/LDV or SOF/RBV were smaller than those of patients treated with DCV/ASV, at each time point (Fig. 4b) .
Regarding the ΔLDL-C values of patients treated with DCV/ASV, SOF/LDV, and SOF/RBV (Fig. 4c) , and the ΔTG values of the patients treated with DCV/ASV, SOF/LDV, and SOF/RBV (Fig. 4d) , the differences were not statistically significant.
DISCUSSION
I N THIS STUDY, we investigated the effects of three IFNfree DAA treatment regimens, DCV/ASV, SOF/LDV, and SOF/RBV, on lipid metabolism in patients with chronic HCV infection. This is the first report to describe the various changes in serum lipid profiles that were seen from baseline to p24w in CHC patients receiving the DAA treatment regimens. Our results confirm that the increases of serum TC and LDL-C during and after IFN-free treatment with DAAs were strongly dependent on the type of treatment regimen. In addition, this is the first report to compare the effects of three IFN-free DAA treatment regimens, DCV/ASV, SOF/LDV, and SOF/RBV, on lipid metabolism over a sufficient period. In short, DCV/ASV resulted in a gradual increase in serum TC and LDL-C during and after treatment, SOF/LDV resulted in a rapid increase during the earlier phase of treatment and a gradual decrease after the later phase of treatment, and SOF/RBV resulted in no significant increase during or after treatment. Our data indicate that the increase of serum LDL-C was the major contributor to the increase of serum TC. This finding is strongly supported by previous reports that the increase of serum TC in this situation is considered to be mainly caused by the increase of LDL-C. 13, 16 Hashimoto et al. compared the serum lipid levels in CHC patients treated with DCV/ASV or SOF/LDV between baseline and treatment day 28. They concluded the increase of serum levels of TC, LDL-C, and HDL-C during treatment was dependent on the treatment regimen. 16 In another report, Endo et al. compared the serum cholesterol in CHC patients treated with DCV/ASV or SOF/LDV at the beginning of treatment and at 4 and 12 weeks after treatment. They concluded serum cholesterol increased significantly during SOF/LDV treatment and HCV elimination was associated with a similar increase in cholesterol after treatment, regardless of the DAA regimen. 18 Although our findings regarding the effects of DCV/ASV and SOF/LDV on lipid metabolism during treatment are similar to their results, our study of serum lipid profiles up to 24 weeks after treatment is unprecedented.
Regarding the relationship between SOF/RBV and host lipid metabolism, Meissner et al. reported a rapid and sustained increase of LDL-C in patients infected with HCV-GT1b and treated with SOF/RBV for 24 weeks. The LDL-C changes persisted after treatment in patients who achieved SVR, whereas the LDL-C dropped to pretreatment levels in patients who failed to eliminate HCV. 15 In that report, an obvious increase in serum LDL-C was correlated with elimination of the virus from the serum, suggesting SOF/RBV has a direct effect on the serum TC level through HCV clearance. 15 However, our results revealed that SOF/RBV resulted in a slighter increase than DCV/ASV, during and after treatment. Although a direct effect of RBV on lipid profiles could not be clarified, RBV might disrupt the increase of LDL-C influenced by HCV eradication. One probable reason is that the patients in the previous report were infected with HCV-GT1, whereas our patients were infected with HCV-GT2. That report indicated that HCV-GT2 eradication affects the lipid profile more favorably than clearance of HCV-GT1, 19 although there was no information about the changes of serum TC and LDL-C. In another report, HCV-associated hypocholesterolemia was shown to be most evident with HCV genotype 3, intermediate with HCV-GT1, and not significant with HCV-GT2. 20 These findings suggest that patients infected with HCV-GT2 have no dyslipidemia before HCV eradication treatment and a significant increase of LDL-C may not be seen during and after treatment.
Although it is well known that disruption of lipid metabolism is a feature of chronic HCV infection, 21, 22 the mechanisms of serum lipid change produced by various DAA regimens remain unclear. It is difficult to explain the obvious difference in the changes of serum lipid profiles caused by DCV/ASV, SOF/LDV, and SOF/RBV, although we suggest there may be different effects of these three treatment regimens on lipid metabolism, in addition to their antiviral action. In a previous report, it was shown that DAAs by themselves may induce pharmacological effects on lipid metabolism. 15 In addition, telaprevir, which is an inhibitor of the NS3/4A protease, 23 inhibits lipid synthesis in vitro, especially expression of the LDL-C receptor. 24 In another report, an increase of the serum LDL-C level was seen as the main independent predictive marker of response to telaprevir-based triple therapy. 25 Regarding these reports, one possible reason for the increase of LDL-C during SOF/LDV treatment is that SOF itself is able to increase serum LDL-C. In addition, NS5A inhibitors, including LDV, may have a synergistic effect with SOF and help to increase LDL-C rapidly, followed by a decline of TC and LDL-C after treatment. Further studies will be required, including investigation of the direct effect of SOF on LDL-C receptor expression.
In our study, a large number of patients experienced significant increases of serum TC and LDL-C, induced by IFN-free DAA treatment. Because lowering of serum LDL-C with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals, 26 management of dyslipidemia is essential to improve the outcome of patients with HCV eradication. A recent report discussed the relationship between the risk of coronary heart disease (CHD) and the serum level of LDL-C in the general Japanese population. 27 In another report, serum levels of LDL-C ranging from approximately 80 mg/dL to 200 mg/dL were positively associated with the risk of CHD in a Japanese cohort. 28 In our results, the serum levels of LDL-C in patients treated with DCV/ASV increased gradually throughout the observation period and reached 124.7 ± 34.8 mg/dL at SVR24, while the maximum level of LDL-C in the patients treated with SOF/LDV was 126.2 ± 32.9 mg/dL at 8w. Further studies of large patient cohorts are needed to survey the relationship between the increase of lipid levels and the progression of CHD after HCV eradication.
This study has some limitations. First, even though the serum lipid profile was confirmed, other parameters that might alter the results, such as a change of body weight, dietary modifications, and the amount of exercise, were not available. Second, because the observation period was limited to 24 weeks after treatment, the long-term changes from HCV eradication by DAA treatment could not be observed. Finally, because DAA treatment can eradicate HCV at a high rate and there were few patients who did not achieve SVR24, we could not compare the lipid profiles of the patients who achieved SVR24 and those who did not.
In conclusion, in addition to an anti-HCV effect, DAAs themselves may have pharmacological effects on serum lipid levels, especially on LDL-C. During treatment with DCV/ASV, SOF/LDV, or SOF/RBV, the change in the serum lipid profile may not be due only to recovery from the disruption of lipid metabolism induced by HCV infection and the features of particular HCV genotypes, but also to the pharmacological effects of DAAs. To elucidate the pharmacologic effect of DAAs on serum lipid profiles, further investigations are needed, especially of the molecular effects of DAAs on host lipid metabolism.
